Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Genitourinary tumours, prostate

618MO - Local therapy to the primary tumour for newly diagnosed, oligo-metastatic prostate cancer: A prospective randomized, phase II, open-label trial

Date

18 Sep 2020

Session

Mini Oral - Genitourinary tumours, prostate

Presenters

Bo Dai

Citation

Annals of Oncology (2020) 31 (suppl_4): S507-S549. 10.1016/annonc/annonc275

Authors

B. Dai1, J. Zhang1, H. Wang1, Q. Wang2, Y. Kong2, Y. Zhu1, X. Qin1, G. Lin1, D. Ye1

Author affiliations

  • 1 Urology, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
  • 2 Pathology, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
More

Resources

Login to access the resources on OncologyPRO.

Abstract 618MO

Background

Oligo-metastatic prostate cancer is recognized as an intermediate stage between localized disease and widespread metastases. The role of radical local therapy (RLT) to the primary tumor for these patients is unclear. We conducted this phase 2 randomized trial to investigate if radical prostatectomy (RP) or prostate radiotherapy (RT) benefits these patients (NCT02742675).

Methods

Oligo-metastases was defined as ≤ 5 bone or extra-pelvic lymph node metastases and no visceral metastases. Patients were randomly assigned (1:1) to receive androgen deprivation therapy (ADT) or ADT plus RLT. For patients allocated to ADT+RLT group, RP was recommended with priority, while RT was administrated to those refused RP and those with unresectable primary tumor after 1-3 months induced ADT. The primary outcome was radiographic progression-free survival (rPFS) and the secondary outcome was overall survival (OS).

Results

A total of 200 patients were enrolled between Sept 1, 2015 and Mar 10, 2019. The median age was 68 years and the median PSA at diagnosis was 98.8 ng/ml. Bone metastases and distant lymph node metastases exited in 96% and 15% of all patients. 96 of 100 patients in ADT+RLT group received RLT including 85 RP and 11 RT. After a median follow-up of 28 months, radiographic progression was observed in 19 of 100 patients in ADT+RLT group and 33 of 100 patients in ADT group. The median rPFS was not reached in ADT+RLT group and 50 months in ADT group (HR = 0.50; 95% CI, 0.28 to 0.87; p = 0.015). RLT related complications occurred in 24 of 85 RP patients (including 3 grade 3-4 complications) and 5 of 11 RT patients. In order to evaluate the OS, longer follow-up period is required.

Conclusions

Local therapy to the primary tumor improves rPFS in patients with newly diagnosed, oligo-metastatic prostate cancer.

Clinical trial identification

NCT02742675.

Editorial acknowledgement

Legal entity responsible for the study

Bo Dai.

Funding

Fudan University Shanghai Cancer Center.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings